Market Research Logo

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
  • The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Growth/Differentiation Factor 8 (Myostatin or GDF-8) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.Global Markets Direct's latest report GrowthDifferentiation Factor 8 – Pipeline Review, H1 2016, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF-8) Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFβ) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 7 respectively.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview
Therapeutics Development
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Stage of Development
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Therapy Area
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Indication
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Atara Biotherapeutics, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Milo Biotechnology LLC
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Scholar Rock, Inc.
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Drug Profiles
AAV1-Foliistatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AAV9-Follistatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landogrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Dormant Projects
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Featured News & Press Releases
May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association
May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients
Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes
Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting
Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting
Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society
Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program
Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association
Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association
May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association
May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia
May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Acceleron Pharma, Inc., H1 2016
Pipeline by Atara Biotherapeutics, Inc., H1 2016
Pipeline by Bristol-Myers Squibb Company, H1 2016
Pipeline by Eli Lilly and Company, H1 2016
Pipeline by Milo Biotechnology LLC, H1 2016
Pipeline by Pfizer Inc., H1 2016
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Pipeline by Sarepta Therapeutics, Inc., H1 2016
Pipeline by Scholar Rock, Inc., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report